Novel germline PALB2 truncating mutations in African American breast cancer patients

Cancer

Volumn 118, Issue 5, 2012, Pages 1362-1370

  Zheng, Yonglan ^a   Zhang, Jing ^a   Niu, Qun ^a   Huo, Dezheng ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

African American; breast cancer; mutation; PALB2; sequencing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; GENOMIC DNA; PROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER PATIENT; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; EXON; FAMILY HISTORY; FANCONI ANEMIA; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; PALB2 GENE; PRIORITY JOURNAL; UNTRANSLATED REGION;

ADULT; AFRICAN AMERICANS; BREAST NEOPLASMS; CARCINOMA; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84857368978     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26388     Document Type: Article

References (43)

1. American Cancer Society. Breast Cancer Overview. Atlanta, GA: American Cancer Society; 2011. Available at:. Accessed May 25, 2011.
2. Fackenthal JD, Olopade OI,. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007; 7: 937-948. (Pubitemid 350165853)
3. Turnbull C, Rahman N,. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet. 2008; 9: 321-345.
4. Tischkowitz M, Xia B,. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res. 2010; 70: 7353-7359.
5. D'Andrea AD,. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010; 362: 1909-1919.
6. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007; 39: 162-164. (Pubitemid 46184345)
7. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007; 39: 159-161. (Pubitemid 46184344)
8. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39: 165-167. (Pubitemid 46184346)
9. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446: 316-319. (Pubitemid 46426155)
10. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A. 2007; 104: 6788-6793. (Pubitemid 47175579)
11. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early onset breast cancer in French-Canadian women [serial online]. Breast Cancer Res. 2007; 9: R83.
12. Garcia MJ, Fernandez V, Osorio A, et al. Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2009; 113: 545-551.
13. Cao AY, Huang J, Hu Z, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009; 114: 457-462.
14. Sluiter M, Mew S, van Rensburg EJ,. PALB2 sequence variants in young South African breast cancer patients. Fam Cancer. 2009; 8: 347-353.
15. Heikkinen T, Karkkainen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009; 15: 3214-3222.
16. Papi L, Putignano AL, Congregati C, et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer. 2010; 9: 181-185.
17. Dansonka-Mieszkowska A, Kluska A, Moes J, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients [serial online]. BMC Med Genet. 2010; 11: 20.
18. Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers- Heijboer H,. PALB2 analysis in BRCA2-like families. Breast Cancer Res Treat. 2011; 127: 357-362.
19. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA,. PALB2: a novel inactivating mutation in a Italian breast cancer family. Fam Cancer. 2010; 9: 531-536.
20. Bogdanova N, Sokolenko AP, Iyevleva AG, et al. PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat. 2011; 126: 545-550.
21. Southey MC, Teo ZL, Dowty JG, et al. A PALB2 mutation associated with high risk of breast cancer [serial online]. Breast Cancer Res. 2010; 12: R109.
22. Peterlongo P, Catucci I, Pasquini G, et al. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat. 2011; 126: 825-828.
23. Casadei S, Norquist BM, Walsh T, et al. Contribution to familial breast cancer of inherited mutations in the BRCA2-interacting protein PALB2. Cancer Res. 2011; 71: 2222-2229.
24. Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011; 10: 225-231.
25. Erkko H, Nikkila J, Butzow R, et al. Occurrence of germline PALB2 mutations in ovarian cancer [abstract]. Proceedings of the 57th Annual Meeting of the American Society of Human Genetics; October 23-27, 2007; San Diego, Calif. Abstract A404/F. Available at:. Accessed April 10, 2010.
26. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene [serial online]. Science. 2009; 324: 217.
27. Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009; 137: 1183-1186.
28. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010; 78: 490-494.
29. Pakkanen S, Wahlfors T, Siltanen S, et al. PALB2 variants in hereditary and unselected Finnish prostate cancer cases [serial online]. J Negat Results Biomed. 2009; 8: 12.
30. Rozen S, Skaletsky HJ,. Primer3 on the WWW for general users and for biologist programmers. In:, Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000: 365-386.
31. Ng PC, Henikoff S,. Predicting deleterious amino acid substitutions. Genome Res. 2001; 11: 863-874. (Pubitemid 32447869)
32. Ramensky V, Bork P, Sunyaev S,. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002; 30: 3894-3900. (Pubitemid 35012462)
33. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M,. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics. 2005; 21: 3176-3178. (Pubitemid 41418475)
34. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003; 13: 2129-2141. (Pubitemid 37161770)
35. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of 8 recurrent substitutions as neutral. J Med Genet. 2006; 43: 295-305.
36. Notredame C, Higgins DG, Heringa J,. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol. 2000; 302: 205-217.
37. Hubbard T, Barker D, Birney E, et al. The ENSEMBL genome database project. Nucleic Acids Res. 2002; 30: 38-41. (Pubitemid 34679498)
38. den Dunnen JT, Antonarakis SE,. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000; 15: 7-12. (Pubitemid 30036162)
39. Wildeman M, van Ophuizen E, den Dunnen JT, Taschner PE,. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum Mutat. 2008; 29: 6-13.
40. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001; 29: 308-311. (Pubitemid 32054478)
41. Wong MW, Nordfors C, Mossman D, et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat. 2011; 127: 853-859.
42. Ding YC, Steele L, Chu LH, et al. Germline mutations in PALB2 in African American breast cancer cases. Breast Cancer Res Treat. 2011; 126: 227-230.
43. Sy SM, Huen MS, Chen J,. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem. 2009; 284: 21127-21131.